Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

Publisher： Karger

E-ISSN： 1421-9794|61|1|41-50

ISSN： 0009-3157

Source： Chemotherapy, Vol.61, Iss.1, 2015-0, pp. : 41-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 4, 2015-04 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation

By  

Chemotherapy, Vol. 59, Iss. 6, 2014-07 ,pp. : 414-419

Karger

Access to resources Recommend Favorite

Pemetrexed for Previously Treated Patients with Non-Small Cell Lung Cancer and Differences in Efficacy according to Thymidylate Synthase Expression

By  

Chemotherapy, Vol. 58, Iss. 4, 2012-11 ,pp. : 313-320

Karger

Access to resources Recommend Favorite

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 472-477

Karger

Access to resources Recommend Favorite